ESMO Asia 2020 Virtual

European Society for Medical Oncology Asia 2020

At the ESMO Asia 2020 Virtual Congress, Boehringer Ingelheim presented the latest data on their approved compound afatinib* in advanced, EGFR mutation-positive lung cancer.

 

Please see below for more information and downloadable versions of our ESMO Asia 2020 publications.

 

 

Virtual exhibit

 

Click here to view our latest virtual exhibit.

 

Friday, November 20 – Sunday, November 22, 2020
Virtual format
Publications

Explore our latest clinical data during the scientific program at ESMO.

Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumor Type
  • All tumor types
Friday, November 20 – Sunday, November 22, 2020
Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC harboring uncommon mutations
Author(s): Yang et al.
Poster Presentation
Tumor Type(s): non-small cell lung cancer (NSCLC)
Presentation Number: 1341P
Sequential afatinib and osimertinib in real-world EGFR mutation-positive (EGFRm+) NSCLC: final analysis of Asian patients in the GioTag study
Author(s): Hochmair et al.
Poster Presentation
Tumor Type(s): non-small cell lung cancer (NSCLC)
Presentation Number: 400P
UpSwinG: real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Author(s): Popat et al.
Poster Presentation
Tumor Type(s): non-small cell lung cancer (NSCLC)
Presentation Number: 420TiP
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

© 2021 Boehringer Ingelheim International GmbH. All rights reserved.

 

Page last updated: January 2021